Last reviewed · How we verify
Arelix — Competitive Intelligence Brief
marketed
piretanide
Solute carrier family 12 member 1
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Arelix (PIRETANIDE).
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Arelix TARGET | PIRETANIDE | marketed | piretanide | Solute carrier family 12 member 1 | ||
| Bumex | BUMETANIDE | marketed | Loop Diuretic [EPC] | Solute carrier family 12 member 1 | 1983-01-01 | |
| Torasemide | Torasemide | Medical University of Warsaw | marketed | Solute carrier family 12 member 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Bumex · 12329731 · Formulation · US
- — Bumex · 11260038 · Method of Use · US
- — Bumex · 11123319 · Formulation · US
Sponsor landscape (piretanide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Arelix CI watch — RSS
- Arelix CI watch — Atom
- Arelix CI watch — JSON
- Arelix alone — RSS
- Whole piretanide class — RSS
Cite this brief
Drug Landscape (2026). Arelix — Competitive Intelligence Brief. https://druglandscape.com/ci/piretanide. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab